Form 4: Redmile Group Increases Stake in ADC Therapeutics SA

Redmile Group, LLC, along with related entities and individuals, reports acquiring 800,000 common shares of ADC Therapeutics SA at $2.81 per share.

Summary

• Redmile Group, LLC, RedCo II Master Fund, L.P., and Jeremy Green reported changes in their beneficial ownership of ADC Therapeutics SA (ADCT) common shares.
• On July 1, 2024, they purchased 800,000 common shares at a price of $2.81 per share.
• 400,000 shares were acquired indirectly through Redmile Clients and 400,000 shares were acquired directly by RedCo II.
• Following the transaction, Redmile Group's beneficial ownership includes 15,669,217 shares held indirectly and 12,995,040 shares held directly.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of share purchases. The increased stake could be seen as a positive, but the disclaimer of beneficial ownership tempers the enthusiasm.

Positives

• The increased investment by Redmile Group could be interpreted as a positive signal regarding their confidence in ADC Therapeutics SA.

Risks

• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest, which could indicate a limited commitment.
• The purchases were effected within a period of less than six months from deemed sales reported in February 2024, which could raise short-swing profit concerns, although the filing states that no additional profits have been earned.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares; this filing indicates changes in Redmile Group's investment in ADC Therapeutics SA.

Stakeholder Impact

• Shareholders may view the increased stake by Redmile Group as a positive signal.

Key Dates